Literature DB >> 22375527

The IL-23/IL-17 pathway in inflammatory bowel disease.

Alessandra Geremia1, Derek P Jewell.   

Abstract

The etiology of inflammatory bowel disease is unknown but available evidence suggests that a deregulated immune response towards the commensal bacterial flora is responsible for intestinal inflammation in genetically predisposed individuals. IL-23 promotes expansion and maintenance of Th17 cells, which secrete the proinflammatory cytokine IL-17 and have been implicated in the pathogenesis of many chronic inflammatory disorders. Recent studies have shown that IL-23 also acts on cells of the innate immune system that can contribute to inflammatory cytokine production and tissue inflammation. A role for the IL-23/IL-17 pathway in the pathogenesis of chronic intestinal inflammation in inflammatory bowel disease has emerged from both animal and human studies. Here we aim to review the recent advances in this rapidly moving field.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22375527     DOI: 10.1586/egh.11.107

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  30 in total

Review 1.  Inflammatory bowel disease: pathogenesis.

Authors:  Yi-Zhen Zhang; Yong-Yu Li
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

2.  Attenuation of NF-κB in Intestinal Epithelial Cells Is Sufficient to Mitigate the Bone Loss Comorbidity of Experimental Mouse Colitis.

Authors:  Ke Ke; Tim Hung-Po Chen; Manoj Arra; Gabriel Mbalaviele; Gaurav Swarnkar; Yousef Abu-Amer
Journal:  J Bone Miner Res       Date:  2019-07-25       Impact factor: 6.741

Review 3.  Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease.

Authors:  Cristina-Sorina Cătană; Ioana Berindan Neagoe; Vasile Cozma; Cristian Magdaş; Flaviu Tăbăran; Dan Lucian Dumitraşcu
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

4.  Increased susceptibility to Trichuris muris infection and exacerbation of colitis in Mdr1a-/- mice.

Authors:  Ekta K Bhardwaj; Kathryn J Else; Michael T Rogan; Geoffrey Warhurst
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

5.  Branched Fatty Acid Esters of Hydroxy Fatty Acids (FAHFAs) Protect against Colitis by Regulating Gut Innate and Adaptive Immune Responses.

Authors:  Jennifer Lee; Pedro M Moraes-Vieira; Angela Castoldi; Pratik Aryal; Eric U Yee; Christopher Vickers; Oren Parnas; Cynthia J Donaldson; Alan Saghatelian; Barbara B Kahn
Journal:  J Biol Chem       Date:  2016-08-29       Impact factor: 5.157

6.  T Cell-Associated Cytokines in the Pathogenesis of Sjögren's Syndrome.

Authors:  Jun-O Jin; Qing Yu
Journal:  J Clin Cell Immunol       Date:  2013-02-26

Review 7.  Implication of miRNAs for inflammatory bowel disease treatment: Systematic review.

Authors:  Wei-Xu Chen; Li-Hua Ren; Rui-Hua Shi
Journal:  World J Gastrointest Pathophysiol       Date:  2014-05-15

8.  Food colorants metabolized by commensal bacteria promote colitis in mice with dysregulated expression of interleukin-23.

Authors:  Zhengxiang He; Lili Chen; Jovani Catalan-Dibene; Gerold Bongers; Jeremiah J Faith; Chalada Suebsuwong; Robert J DeVita; Zeli Shen; James G Fox; Juan J Lafaille; Glaucia C Furtado; Sergio A Lira
Journal:  Cell Metab       Date:  2021-05-13       Impact factor: 31.373

9.  IL6 genetic variants haplotype is associated with susceptibility and disease activity but not with therapy response in patients with inflammatory bowel disease.

Authors:  Beatriz Piantoni Gonçalves; Tamires Flauzino; Cláudia Junko Inoue; Jaqueline Costa Castardo de Paula; Talita Cristina Galvão; Camila Cataldi de Alcantara; Paula Kikuchi Miyazaki; Lucilene Rosa; Silva Westmore; Marcell Alysson Batisti Lozovoy; Edna Maria Vissoci Reiche; Andréa Name Colado Simão
Journal:  Int J Colorectal Dis       Date:  2020-10-12       Impact factor: 2.571

10.  Molecular Targets and Mechanisms of Scutellariae radix-Coptidis rhizoma Drug Pair for the Treatment of Ulcerative Colitis Based on Network Pharmacology and Molecular Docking.

Authors:  Kai Niu; Qifang Li; Yuan Liu; Yi Qiao; Bingbing Li; Chao Wei; Kunrui Wang; Lu'an Cui; Canlei Zheng; Rong Wang; Li Zhang; Honghua Zhang; Bing Sun; Bin Yu
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-04       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.